


RECEIVED

JUN 20 2002

TECH CENTER 1600-2900



SEQUENCE LISTING

COPY OF PAPERS
ORIGINALLY FILED

<110> Max-Delbrück-Centrum für Molekulare Medizin

<120> Tumor vaccines for muc1-positive carcinomas

<130> 0107-027

<140> Ser. No. 09/606,910

<141> 2000-06-29

<150> DE 197 58 400.4

<151> 1997-12-30

<150> PCT/DE98/03819

<151> 1998-12-30

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 7

<212> PRT

<213> human

<220>

<223> immunodominant region of MUC1

<400> 1

Pro Asp Thr Arg Pro Ala Pro

1

5

<210> 2

<211> 8

<212> PRT

<213> mouse, IgG1

<220>

<223> A76-A/C7 epitope

<400> 2

Ala Pro Asp Thr Arg Pro Ala Pro

1

5

<210> 3
 <211> 6
 <212> PRT
 <213> mouse, IgG1

<220>
 <223> MFO6 epitope

<400> 3
 Asp Thr Arg Pro Ala Pro
 1 5

<210> 4
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: designed
 synthetical glycopeptide

<400> 4
 Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser
 1 5 10 15

Thr Ala Pro Pro Ala
 20

<210> 5
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: designed
 synthetical glycopeptide

<400> 5

